Exchange: NASDAQ·Updated 07:52 PM EDT
BEAM logo

BEAM Beam Therapeutics Inc

$25.70
$1.10
(4.47%)
Today
Closed $25.70
$0.00
(0.00%)
After Hours
EarningsNov 3
Mkt Cap$2.54B
Vol1.8M

About BEAM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
31

Bearish Sentiment

How do you feel about BEAM?

Bastox
$BEAM Mega Buy! Bank of America purchased 720,648 Beam Therapeutics shares worth approximately $24.73 million, giving it a 0.70% stake. Institutional investors collectively own 99.68% of the company.
3
LookNoHands
$BEAM 🚨 Meaningful BEAM development today, September 30: Beam Therapeutics⁠ has filed a lawsuit alleging that former Beam scientist Zi Jun “Emma” Wang misappropriated confidential base-editing technology and used it to help create YolTech Therapeutics. The dispute is particularly relevant because YolTech's YOLT-202/SERP-01 targets AATD—the same disease as BEAM-302—and uses base editing. Beam alleges Wang secretly co-founded YolTech while still employed at Beam and that the competing AATD program was developed using Beam trade secrets. The commercial stakes are potentially substantial: YolTech recently licensed SERP-01 outside Greater China to Serapha Bio in a deal containing more than 2 billion dollars in potential milestones, and Serapha is also named in Beam's lawsuit. Serapha denies the allegations.
1
BarneyR
$BEAM Extreme short squeeze candidates. Beam nearly 39% short. Good news will send this flying.
1
Trackdips
99% bounce probability. That was $BEAM on my Buy the Dip Tracker. I entered at $25.26 and exited at $26.38 for a +4.4% gain. Want access to the tracker and see my personal buys & sells in real time? Join the Patreon → link in bio.
1
jewell69
$BEAM 9/28 10:39 am edt trying 2 bi 200 23.81 now offered at .88 No approved drugs today. CAR-T type. Seeking lung drug approval. Stock fell tons around 9/18
jewell69
$BEAM it makes me feel like I don't want 2 b holding the bag ! re-entry today 9/23. wow, sooo cheap (hope it isn't 'cheap 4 a reason' 09/23/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $24.37 -$4,874.00 More 08/25/2026 Sell BEAM BEAM THERAPEUTICS INC 200 $30.92 $0.17 $6,183.83 More 08/24/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $28.70 -$5,740.00 More 08/17/2026 Sell BEAM BEAM THERAPEUTICS INC 200 $27.165 $0.15 $5,432.85 More 08/12/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $26.88 -$5,376.00
jewell69
$BEAM sticker shock IN A POSITIVE WAY. now at 24.41 9/23 2:40 pm edt. placed a b order, b on market close 200. recent trades 08/25/2026 Sell BEAM BEAM THERAPEUTICS INC 200 $30.92 $0.17 $6,183.83 More 08/24/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $28.70 -$5,740.00 More 08/17/2026 Sell BEAM BEAM THERAPEUTICS INC 200 $27.165 $0.15 $5,432.85 More 08/12/2026 Buy BEAM BEAM THERAPEUTICS INC 200 $26.88 -$5,376.00
Bastox
$BEAM Cathie Woods buying big again today In the healthcare sector, ARK added 102,565 shares of Beam Therapeutics Inc. (NASDAQ:BEAM) to its ARKG ETF, with a total purchase value of $2,558,996. This purchase aligns with ARK’s ongoing interest in innovative biotech firms.
Bastox
$BEAM Cathie Woods buying big again today: In the healthcare sector, ARK added 102,565 shares of Beam Therapeutics Inc. (NASDAQ:BEAM) to its ARKG ETF, with a total purchase value of $2,558,996. This purchase aligns with ARK’s ongoing interest in innovative biotech firms.

Advertisement|Remove ads.